- Delivering Pan India
Bdenza® (Enzalutamide) 40 mg and 80 mg capsules and 160 mg tablets by BDR Pharmaceuticals. Genuine stock supplied in bulk/wholesale quantities to hospitals and pharmacies across India by A.K. Pharma, a licensed pharmaceutical distributor in Delhi.
| Composition | Enzalutamide 40 mg / 80 mg / 160 mg |
|---|---|
| Manufacturer | BDR Pharmaceuticals |
| Country | India |
| Pack size | 40 mg: 4 x 28 capsules; 80 mg: 4 x 14 capsules; 160 mg: 4 x 7 tablets |
| Storage | Store in original pack as per carton instructions |
Supplied only against a valid prescription from a registered medical practitioner.
Sourced from authorised channels
Temperature-controlled packing
Hospitals, clinics, pharmacies
Delhi drug licence holder
Bdenza® (Enzalutamide) 40 mg, 80 mg and 160 mg — Androgen Receptor Inhibitor: A Sourcing Guide for Hospitals and Oncology Pharmacies
Bdenza® is a brand of enzalutamide, an androgen receptor inhibitor, marketed by BDR Pharmaceuticals. According to the US prescribing information for the reference product (Xtandi®), enzalutamide is indicated for adults with castration-resistant prostate cancer (CRPC), metastatic castration-sensitive prostate cancer (mCSPC), and non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis. The decision to prescribe enzalutamide, including patient selection, dose and monitoring, rests entirely with the treating physician. This page provides sourcing and procurement information for hospitals and pharmacies, not clinical or treatment guidance.
As both a trusted medicine distributor in Delhi and a licensed pharmaceutical distributor in Delhi, A.K. Pharma supplies genuine Bdenza® (enzalutamide) 40 mg capsules, 80 mg capsules and 160 mg tablets to hospitals, oncology centres and pharmacies across India. Buyers comparing pharmaceutical distribution companies and wholesale pharmaceutical distributors can also browse our full product range and the cancer medicines category. Supply is in bulk/wholesale quantities only.
Bdenza contains enzalutamide, an oral androgen receptor (AR) inhibitor. All three Bdenza presentations on this page contain the same active ingredient and differ in strength and dosage form.
How it works, according to the label: The prescribing information describes enzalutamide as acting on the androgen receptor signalling pathway at several steps: it blocks androgens from binding to the receptor, prevents the activated receptor from moving into the cell nucleus, and impairs the receptor’s binding to DNA. In laboratory studies this reduced the growth of prostate cancer cells.
The current US prescribing information for Xtandi® (enzalutamide; DailyMed) lists the following. Indications in India and other countries may differ and are defined by each country’s regulator.
The studies below are summarised as published; they describe the evidence behind enzalutamide, the active ingredient, and are not a recommendation for any patient.
Bdenza is a brand of enzalutamide marketed in India; these trials were conducted with the reference product. The approved prescribing information governs.
| Strength | Dosage form | Pack size (as shown on the carton) |
|---|---|---|
| Enzalutamide 40 mg | Capsules | 4 x 28 capsules |
| Enzalutamide 80 mg | Capsules | 4 x 14 capsules |
| Enzalutamide 160 mg | Tablets | 4 x 7 tablets |
Pack details are listed as printed on the cartons; please confirm the current pack and batch with us before ordering. Dose and regimen must be determined and followed exactly as directed by the treating physician and the approved prescribing information.
This page is written for hospital pharmacists, oncology department buyers, and pharmacies that source specialty oncology products. Enzalutamide is prescribed and supervised by a physician, as described in the prescribing information.
The US prescribing information for Xtandi® reports that the most common adverse reactions (10% or more, and at least 2% more frequent than placebo) were musculoskeletal pain, fatigue, hot flush, constipation, decreased appetite, diarrhoea, hypertension, haemorrhage, fall, fracture and headache. Warnings listed include seizure, posterior reversible encephalopathy syndrome (PRES), hypersensitivity, ischaemic heart disease, and falls and fractures. This list is not complete; the full prescribing information governs.
All use should follow the approved prescribing information and the instructions of the treating physician.
Please follow the storage instructions printed on the Bdenza carton and leaflet. Keep in the original pack, out of reach of children.
Bdenza is marketed by BDR Pharmaceuticals. A.K. Pharma is a licensed distributor and does not manufacture the product. As one of the pharmaceutical distributors serving Indian hospitals, we source Bdenza through authorised channels and supply it with pack and batch details. Buyers comparing a pharmaceutical wholesale distributors list or a pharma distribution company can verify our credentials on the About Us page.
Is Bdenza available in India?
A.K. Pharma supplies Bdenza (enzalutamide) 40 mg capsules, 80 mg capsules and 160 mg tablets to hospitals and pharmacies in India. Contact us for current availability.
What does Bdenza contain?
Enzalutamide, an androgen receptor inhibitor, in 40 mg and 80 mg capsules and 160 mg tablets.
Can I order a single pack?
A.K. Pharma is a distributor and supplies bulk/wholesale quantities only, not one or two pieces.
How should Bdenza be stored?
As printed on the carton and leaflet, in the original pack.
Does A.K. Pharma advise on dosing or suitability?
No. Treatment decisions, including dosing, rest solely with the treating physician and the approved prescribing information.
How do I request a quote?
Call or WhatsApp us, or use the contact details below.
📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052
📞 011 4172 6999
📱 WhatsApp: +91 9810034827
🌐 akpharma.in
Disclaimer: This page is intended for informational and sourcing/procurement purposes only and does not constitute medical or clinical advice. A.K. Pharma is a licensed medicine distributor, not a healthcare provider, and does not provide clinical guidance. All treatment decisions, including drug selection and dosing, rest solely with the treating physician and should follow the approved prescribing information.
